Bolero 2 overall survival 2014

Novartis reports data at EBCC-9 for secondary survival endpoint of. 1LBA Everolimus plus exemestane for hormone receptor-positive. The Role of Everolimus Right Now—Advanced Breast Cancer.

Highlights from the 9th European Breast Cancer Conference. The BOLERO-2 study confirms everolimus and exemestane in ER.

19 Mar 2014 Everolimus plus exemestane extended overall survival, a secondary endpoint, by 44 Basel, March 19, 2014 - Results from the secondary endpoint of the Phase III "The BOLERO-2 trial shows that treatment with Afinitor in. 9Th EBCC 19-21 March 2014, Glasgow, Scotland. T. Feys, MSc Overall survival results of BOLERO-2 improved progression-free survival (PFS) by more than. 26 Sep 2011 The BOLERO-2 study confirms everolimus and exemestane in ER/PR+ had an improved progression-free survival of nearly seven months About 50% had disease prior tamoxifen, so in overall more than 50% had. 2014 Cancer Intelligence, all rights reserved Website design by: Still Motion Design.

Everolimus in the treatment of patients with breast cancer - SWOG

Volume 50, Supplement 3, Page S1, March 2014 factor receptor-2-negative ( HER2–) advanced breast cancer (BC): overall survival results from BOLERO-2. BOLERO-2 is published in The New England Journal of Medicine1 and results will be survival but no benefit in terms of overall survival at the most recent update. Dr. Lee Schwartzberg's ESMO 2014 Recommendations in Breast Cancer.

Progression-free or overall survivalrevisited in BOLERO-2

1LBA Everolimus plus exemestane for hormone receptor-positive. The Role of Everolimus Right Now—Advanced Breast Cancer. BOLERO-2 is published in The New England Journal of Medicine1 and results will be survival but no benefit in terms of overall survival at the most recent update. Dr. Lee Schwartzberg's ESMO 2014 Recommendations in Breast Cancer.

The BOLERO-2 study confirms everolimus and exemestane in ER. Novartis reports data at EBCC-9 for secondary survival endpoint of.

Highlights from the 9th European Breast Cancer Conference.

19 Mar 2014 Everolimus plus exemestane extended overall survival, a secondary endpoint, by 44 Basel, March 19, 2014 - Results from the secondary endpoint of the Phase III "The BOLERO-2 trial shows that treatment with Afinitor in. Volume 50, Supplement 3, Page S1, March 2014 factor receptor-2-negative ( HER2–) advanced breast cancer (BC): overall survival results from BOLERO-2. 9Th EBCC 19-21 March 2014, Glasgow, Scotland. T. Feys, MSc Overall survival results of BOLERO-2 improved progression-free survival (PFS) by more than.